https://mindmedicinelaw.com/briefing/psychedelic-activists-challenge-restrictive-sharing-law-in-u-s-20260623-15946The Psychedelic Journalen2026-06-23T22:03:45.136817+00:00Psychedelic Activists Challenge Restrictive Sharing Law in U.S.psychedelic policy, referendum, drug regulation, community advocacy, psychedelic sharing, grassroots movements, public health, legal challenges, U.S. law, psychedelic researchhttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-depression-treatment-current-insights-20260622-15879The Psychedelic Journalen2026-06-23T22:03:30.970419+00:00Ketamine's Role in Depression Treatment: Current Insightsketamine, depression treatment, treatment-resistant depression, suicidal ideation, NMDA receptor, antidepressant, clinical trials, long-term safety, synaptic plasticityhttps://mindmedicinelaw.com/briefing/opioid-receptor-activation-by-ketamine-and-pcp-implications-20260622-15878The Psychedelic Journalen2026-06-23T22:03:19.253949+00:00Opioid Receptor Activation by Ketamine and PCP: Implicationsketamine, PCP, opioid receptors, NMDAR, therapeutic potential, abuse potential, clinical guidelines, drug development, pharmacology, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/rising-ketamine-use-spurs-safety-concerns-in-the-u-s-20260622-15793The Psychedelic Journalen2026-06-23T15:05:20.100334+00:00Rising Ketamine Use Spurs Safety Concerns in the U.S.ketamine safety, non-clinical ketamine use, ketamine regulation, psychedelic therapy, NMDA receptor antagonist, public health concerns, ketamine misuse, mental health treatment, substance use disorder, regulatory scrutinyhttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-treating-concussion-symptoms-20260622-15630The Psychedelic Journalen2026-06-22T22:04:43.326523+00:00Psilocybin's Potential in Treating Concussion Symptomspsilocybin, concussion treatment, neuroplasticity, psychedelic medicine, clinical trials, neuroinflammation, FDA, EMA, brain injury, public healthhttps://mindmedicinelaw.com/briefing/meditation-s-potential-role-in-psilocybin-therapy-a-new-study-20260622-15469The Psychedelic Journalen2026-06-22T22:04:32.092137+00:00Meditation's Potential Role in Psilocybin Therapy: A New Studypsilocybin therapy, meditation and psychedelics, psychedelic research, mental health treatment, mindfulness practices, clinical trials, neuroplasticity, brain connectivity, therapeutic outcomes, psychedelic therapy protocolshttps://mindmedicinelaw.com/briefing/definium-s-lsd-therapy-advances-in-late-stage-depression-trial-20260622-15629The Psychedelic Journalen2026-06-22T22:04:19.562281+00:00Definium's LSD Therapy Advances in Late-Stage Depression TrialLSD therapy, major depression, psychedelic research, clinical trials, FDA approval, mental health treatment, serotonin receptors, psychedelic-assisted therapy, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/safety-concerns-in-expanding-ketamine-clinics-and-delivery-20260622-15471The Psychedelic Journalen2026-06-22T15:05:25.371456+00:00Safety Concerns in Expanding Ketamine Clinics and Deliveryketamine clinics, at-home delivery, patient safety, regulatory oversight, mental health treatment, ketamine therapy, FDA guidelines, treatment efficacy, safety concerns, clinical trialshttps://mindmedicinelaw.com/briefing/definium-s-lsd-formula-achieves-top-results-in-depression-trial-20260622-15468The Psychedelic Journalen2026-06-22T15:04:51.724032+00:00Definium's LSD Formula Achieves Top Results in Depression TrialDefinium Pharmaceuticals, LSD depression trial, psychedelic research, mental health treatment, serotonin receptors, regulatory approvals, treatment-resistant depression, psychedelic compoundshttps://mindmedicinelaw.com/briefing/friction-theoretic-framework-new-insights-for-chronic-diseases-20260621-15389The Psychedelic Journalen2026-06-22T22:04:53.128391+00:00Friction-Theoretic Framework: New Insights for Chronic Diseasesfriction-theoretic framework, multi-scale disease progression, treatment-resistant depression, chronic diseases, multi-target therapies, clinical trials, autoimmune diseases, cancer treatment, Metabolic Control Analysis, public health policyhttps://mindmedicinelaw.com/briefing/new-trial-design-framework-for-psychedelic-research-20260621-15388The Psychedelic Journalen2026-06-22T15:05:02.385556+00:00New Trial Design Framework for Psychedelic Researchpsychedelic research, trial design, ketamine, psilocybin, treatment-resistant depression, compound-race-pathology, psychiatric conditions, post-viral conditions, autoimmune conditions, clinical trialshttps://mindmedicinelaw.com/briefing/orexin-receptor-treatment-in-stress-models-new-insights-20260620-15867The Psychedelic Journalen2026-06-23T22:03:54.575245+00:00Orexin Receptor Treatment in Stress Models: New Insightsorexin receptor treatment, neuroplasticity, stress models, anxiety disorders, depression therapy, psychiatric disorders, basolateral amygdala, preclinical research, neurocircuitry, therapeutic approacheshttps://mindmedicinelaw.com/briefing/ineupatorolide-b-s-antidepressant-potential-via-gut-brain-axis-20260620-15395The Psychedelic Journalen2026-06-22T22:05:13.735722+00:00Ineupatorolide B's Antidepressant Potential via Gut-Brain Axisineupatorolide B, antidepressant effects, gut-brain axis, vagus nerve, microbiota-targeted therapy, depression research, preclinical study, mental health treatment, synaptic protein expression, short-chain fatty acidshttps://mindmedicinelaw.com/briefing/ebselen-trial-in-depression-limited-connectivity-changes-20260620-15393The Psychedelic Journalen2026-06-22T22:05:00.775583+00:00Ebselen Trial in Depression: Limited Connectivity Changesebselen, depression treatment, resting-state functional connectivity, clinical trial, brain connectivity, antidepressant adjuncthttps://mindmedicinelaw.com/briefing/emerging-psychedelic-therapies-for-bipolar-depression-20260620-15394The Psychedelic Journalen2026-06-22T15:05:37.424940+00:00Emerging Psychedelic Therapies for Bipolar Depressionpsilocybin, ketamine, bipolar disorder, treatment-resistant depression, psychedelic therapies, clinical trials, neuromodulation, mental health, pharmacology, psychiatric carehttps://mindmedicinelaw.com/briefing/canmat-2023-guidelines-on-treatment-resistant-depression-20260619-15070The Psychedelic Journalen2026-06-23T15:05:52.798976+00:00CANMAT 2023 Guidelines on Treatment-Resistant DepressionCANMAT 2023 guidelines, treatment-resistant depression, ketamine, esketamine, psychedelic substances, mental health care, clinical trials, long-term efficacy, pharmacological strategies, non-pharmacological strategieshttps://mindmedicinelaw.com/briefing/cognitive-energy-landscape-insights-from-infancy-to-adolescence-20260619-15026The Psychedelic Journalen2026-06-23T15:05:39.337306+00:00Cognitive Energy Landscape: Insights from Infancy to Adolescencecognitive development, brain maturation, network control theory, diffusion MRI, neurodevelopmental disorders, control energy, cognitive tasks, molecular-level influences, myelination, neurodevelopmental researchhttps://mindmedicinelaw.com/briefing/ketamine-assisted-psychotherapy-for-ptsd-review-insights-20260619-15457The Psychedelic Journalen2026-06-22T15:05:12.814140+00:00Ketamine-Assisted Psychotherapy for PTSD: Review Insightsketamine-assisted psychotherapy, PTSD treatment, systematic review, meta-analysis, psychedelic therapy, clinical guidelines, treatment predictors, mental health policy, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/adaptive-charge-modulation-in-spinal-cord-stimulation-20260618-15074The Psychedelic Journalen2026-06-23T22:04:14.249082+00:00Adaptive Charge Modulation in Spinal Cord Stimulationadaptive charge modulation, spinal cord stimulation, neuromodulation, deep tissue activation, clinical trials, neuroscience, neural interfaces, high-frequency stimulation, regulatory frameworks, chronic stabilityhttps://mindmedicinelaw.com/briefing/bayesian-optimization-enhances-lifu-neuromodulation-precision-20260618-15073The Psychedelic Journalen2026-06-23T22:04:03.826796+00:00Bayesian Optimization Enhances LIFU Neuromodulation PrecisionBayesian optimization, LIFU neuromodulation, BEACUN, functional ultrasound imaging, personalized medicine, clinical trialshttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-proposal-for-ptsd-in-australia-20260618-15046The Psychedelic Journalen2026-06-23T15:06:27.643413+00:00MDMA-Assisted Therapy Proposal for PTSD in AustraliaMDMA therapy, PTSD treatment, Australia healthcare, psychedelic research, public health, clinical trials, psychedelic policy, therapy safety, mental health, international collaborationhttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-cluster-headache-treatment-20260618-15355The Psychedelic Journalen2026-06-23T15:06:10.141782+00:00Psilocybin's Potential in Cluster Headache Treatmentpsilocybin, LSD, cluster headaches, clinical trials, psychedelic research, smoking cessation, quality of life, mental health, testosterone deficiency, public healthhttps://mindmedicinelaw.com/briefing/telehealth-ketamine-therapy-safety-and-feasibility-in-us-study-20260617-15792The Psychedelic Journalen2026-06-23T15:05:06.363286+00:00Telehealth Ketamine Therapy: Safety and Feasibility in US Studytelehealth ketamine therapy, psychedelic treatment, mental health care, remote therapy, depression treatment, anxiety therapy, PTSD treatment, digital health solutions, subcutaneous ketamine, psychedelic researchhttps://mindmedicinelaw.com/briefing/crispr-enhances-psilocybin-production-in-e-coli-20260613-15458The Psychedelic Journalen2026-06-22T15:05:48.230907+00:00CRISPR Enhances Psilocybin Production in E. coliCRISPR, psilocybin production, E. coli, DMT biosynthesis, genetic engineering, psychedelic research, clinical trials, biotechnology, therapeutic applications, regulatory implications